Hledání článků
Filtry
Thompson S, James M, Wiebe N, et al.; Alberta Kidney Disease Network. Cause of death in patients with reduced kidney function. J Am Soc Nephrol 2015;26:2504–2511.
Navaneethan S, Schold J, Arrigain S, et al. Cause‑specific deaths in non‑dialysis dependent chronic kidney disease. J Am Soc Nephrol 2015;26: 2512–2520.
Matsui M, Uemura S, Takeda Y, et al.; NARA.CKD Investigators. Placental growth factor as a predictor of cardiovascular events in patients with CKD from the NARA.CKD Study. J Am Soc Nephrol 2015;26:2871.2881.
Koyner JL, Davison DL, Brasha‑Mitchell E, et al. Furosemide stress test and biomarkers for the prediction of AKI severity. J Am Soc Nephrol 2015;26:2023–2031.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015, doi: 10.1056/NEJMoa1504720, publikováno online 17. 9. 2015.
Germain DP, Charrow J, Desnick RJ, et al. Ten‑year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 2015;52:353–358.
Sautenet B, Caille A, Giraudeau B, et al. Deficits in information transfer between hospital‑based and primary‑care physicians, the case of kidney disease: a cross‑sectional study. J Nephrol 2015;28:563–570.
Peters SAE, Bots ML, Canaud B, et al., on behalf of the HDF Pooling Project Investigators. Haemodiafiltration and mortality in end‑stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials. Nephrol Dial Transplant 2015 Oct 22; doi:10.1093/ndt/gfv349 V posledních letech
Grams ME, Sang Y, Levey AS, et al. Kidney‑failure risk projection for the living kidney‑donor candidate. N Engl J Med 2015 Nov 6. [Epub ahead of print].
Boils CL, Nasr SH, Walker PD, Couser WG, Larsen CP. Update on endocarditis‑associated glomerulonephritis. Kidney Int 2015;87:1241–1249.
Drechsler C, Kalim S, Wenger JB, Suntharalingam P, Hod T, Thadhani RI, Karumanchi SA, Wanner C, Berg AH. Protein carbamylation is associated with heart failure and mortality in diabetic patients with end‑stage renal disease. Kidney Int 2015;87:1201–1208.
De Zeeuw D, Bekker P, Henkel E, et al. The effect of CCR2 inhibitor CCX140‑B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol 2015;3:687–696.
Gevers T, Ho J, Monshouwer R, Dekker H, Wetzels J, Drenth J. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver Int 2015;35:1607–1614.
Weir MA, Dixon SN, Fleet JL. β‑blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 2015;26:987–996.
Han SS, Park JY, Kang S, et al. Dialysis modality and mortality in the elderly: a meta‑analysis. Clin J Am Soc Nephrol 2015;10:983–993.